The Biomedical Advanced Research and Development Authority (BARDA), under the Department of Health and Human Services (HSS), has extended the deadline for vaccine companies to submit proposals for Pandemic Influenza Medical Countermeasures under Solicitation 11-100-SOL-00020. The new cut-off date is April 20, 2012.
The BARDA Strategic Plan 2011-2016 calls for enhanced development and procurement of countermeasures for pandemic influenza preparedness and response. This resultant Request for Proposal (RFP) is open to companies that currently produce inactivated, recombinant and Live Attenuated Influenza Vaccine (LAIV), seasonal, pre-pandemic and pandemic influenza vaccine at commercial scale.
Included in a comprehensive list of RFP requirements are: master and working virus seed for production of influenza pre-pandemic and pandemic vaccine product; production at small scale, clinical and commercial scale of influenza pre-pandemic and pandemic vaccine and adjuvant; non-clinical and clinical studies using pre-pandemic and pandemic influenza vaccine; storage and shipping shipping services; and vaccine and adjuvant stability studies.
BARDA has estimated an award on this competition to be announced in August 2012, with the possibility of multiple awards. The anticipated period of performance will be for a total of up to five years with the potential for two additional year-long option periods.
